Cargando…
Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
Cancer therapy has entered a new era, transitioning from unspecific chemotherapeutic agents to increasingly specific immune-based therapeutic strategies. Among these, chimeric antigen receptor (CAR) T cells have shown unparalleled therapeutic potential in treating refractory hematological malignanci...
Autores principales: | Stoiber, Stefan, Cadilha, Bruno L., Benmebarek, Mohamed-Reda, Lesch, Stefanie, Endres, Stefan, Kobold, Sebastian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562702/ https://www.ncbi.nlm.nih.gov/pubmed/31108883 http://dx.doi.org/10.3390/cells8050472 |
Ejemplares similares
-
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
por: Benmebarek, Mohamed-Reda, et al.
Publicado: (2019) -
Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job
por: Schwerdtfeger, Melanie, et al.
Publicado: (2021) -
High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy
por: Rataj, Felicitas, et al.
Publicado: (2018) -
Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners
por: Stock, Sophia, et al.
Publicado: (2022) -
A modular and controllable T cell therapy platform for acute myeloid leukemia
por: Benmebarek, Mohamed-Reda, et al.
Publicado: (2021)